Results 261 to 270 of about 300,632 (358)

The Vasopressin-sensitive Adenylate Cyclase of the Rat Kidney

open access: hybrid, 1974
Rabary M. Rajerison   +4 more
openalex   +1 more source

Soluble Guanylate Cyclase Stimulator, BAY41-8543: A Promising Approach for the Treatment of Chronic Heart Failure Caused by Pressure and Volume Overload. [PDF]

open access: yesPharmacol Res Perspect
Martišková A   +8 more
europepmc   +1 more source

New insights into the putative role of leucine-rich repeat proteins of Leptospira interrogans and their participation in host cell invasion: an in silico analysis. [PDF]

open access: yesFront Cell Infect Microbiol
Foltran BB   +9 more
europepmc   +1 more source

Targeted protein degradation of PDE4 shortforms by a novel proteolysis targeting chimera

open access: yesThe FEBS Journal, EarlyView.
Here, we report KTX207, a previously undescribed cereblon‐based PDE4 PROTAC that can specifically target PDE4D shortform for degradation. We showed that KTX207 could improve selectivity, potency and enable a long‐lasting effect when used at a sub‐nanomolar concentration.
Yuan Yan Sin   +16 more
wiley   +1 more source

Stretch regulation of β2-Adrenoceptor signalling in cardiomyocytes requires caveolae. [PDF]

open access: yesCardiovasc Res
Fu J   +8 more
europepmc   +1 more source

A signal transduction blind spot: the function of adenylyl cyclase transmembrane domains

open access: yesThe FEBS Journal, EarlyView.
Transmembrane adenylyl cyclases (tmACs) are essential for synthesising the universal second messenger cyclic AMP. All tmACs share a common topology that includes a large 12‐helix transmembrane (TM) domain. This domain accounts for ~ 35% of the coding sequence but its function is still an open question.
Ryan S. Dowsell, Matthew G. Gold
wiley   +1 more source

A PDE4 shortform degrader: a first in isoform‐specific PDE4 inhibition

open access: yesThe FEBS Journal, EarlyView.
Clinically used phosphodiesterase 4 (PDE4) inhibitors lack selectivity for PDE4 enzyme isoforms, which leads to documented side effects. Building in enzyme selectivity has proved difficult because all PDE4 enzymes share highly conserved catalytic domains. The report by Sin et al.
Donald H. Maurice
wiley   +1 more source

Home - About - Disclaimer - Privacy